Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

By I. Songun, Hein Putter, E. Kranenbarg, M. Sasako, C. van de Velde. The Lancet Oncology, 2010

1,644 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. (2014, background): “The fall in gastric cancer is mainly due to the decline in the prevalence of Helicobacter pylori (H. pylori) infection and tobacco smoking, and to the improvements in food preservation and diet [4].”
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “Long-term (15-year) follow-up from the Dutch trial demonstrated fewer locoregional recurrences and gastric cancer-related deaths with D2 resection; however, this was offset slightly by an increase in postoperative mortality and morbidity [24].”
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. (2011, result): “Although a Dutch trial comparing D1 with D2 gastrectomy reported negative results,(16,18) a 15-year follow-up study showed that the rate of mortality from gastric cancer was significantly lower in the D2 gastrectomy group.(19) Thus, the most recent European Society for Medical Oncology (ESMO) clinic”